BofA upgraded Apollo Medical to Buy from Neutral with a price target of $55, up from $44. The firm sees an inflection point in the growth story, with “high confidence” in the path to sustaining 30%-40%-plus revenue and 20%-plus EBITDA growth through at least 2026. As a result, it is raising its estimates above the Street, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMEH:
- Apollo Medical Holdings Announces Strategic Acquisitions
- Apollo Medical Holdings Issues 631K Shares in Private Sale
- Evercore says Apollo deal ‘doesn’t sound like a big risk’ to Privia
- Apollo Medical partners with BASS Medical Group
- Apollo Medical Holdings Shifts to New Ticker ASTH
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue